166 related articles for article (PubMed ID: 12887055)
1. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intracellular cathepsin activities and suppression of immune responses mediated by helper T lymphocyte type-2 by peroral or intraperitoneal administration of vitamin B6.
Katunuma N; Matsui A; Endo K; Hanba J; Sato A; Nakano M; Yuto Y; Tada Y; Asao T; Himeno K; Maekawa Y; Inubushi T
Biochem Biophys Res Commun; 2000 May; 272(1):151-5. PubMed ID: 10872819
[TBL] [Abstract][Full Text] [Related]
3. Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption.
Katunuma N; Matsunaga Y; Matsui A; Kakegawa H; Endo K; Inubushi T; Saibara T; Ohba Y; Kakiuchi T
Adv Enzyme Regul; 1998; 38():235-51. PubMed ID: 9762356
[TBL] [Abstract][Full Text] [Related]
4. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin S inhibitors as novel immunomodulators.
Thurmond RL; Sun S; Karlsson L; Edwards JP
Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity.
Saegusa K; Ishimaru N; Yanagi K; Arakaki R; Ogawa K; Saito I; Katunuma N; Hayashi Y
J Clin Invest; 2002 Aug; 110(3):361-9. PubMed ID: 12163455
[TBL] [Abstract][Full Text] [Related]
7. Advances in cathepsin S inhibitor design.
Link JO; Zipfel S
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin S dominates autoantigen processing in human thymic dendritic cells.
Stoeckle C; Quecke P; Rückrich T; Burster T; Reich M; Weber E; Kalbacher H; Driessen C; Melms A; Tolosa E
J Autoimmun; 2012 Jun; 38(4):332-43. PubMed ID: 22424724
[TBL] [Abstract][Full Text] [Related]
9. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
[TBL] [Abstract][Full Text] [Related]
10. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
Gupta S; Singh RK; Dastidar S; Ray A
Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
[TBL] [Abstract][Full Text] [Related]
11. Study of the functional share of lysosomal cathepsins by the development of specific inhibitors.
Katunuma N; Matsui A; Kakegawa T; Murata E; Asao T; Ohba Y
Adv Enzyme Regul; 1999; 39():247-60. PubMed ID: 10470376
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
[TBL] [Abstract][Full Text] [Related]
13. Identification of a potent and selective noncovalent cathepsin S inhibitor.
Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
[TBL] [Abstract][Full Text] [Related]
14. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
[TBL] [Abstract][Full Text] [Related]
15. Structure-based development of specific inhibitors for individual cathepsins and their medical applications.
Katunuma N
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(2):29-39. PubMed ID: 21321479
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
Asagiri M; Hirai T; Kunigami T; Kamano S; Gober HJ; Okamoto K; Nishikawa K; Latz E; Golenbock DT; Aoki K; Ohya K; Imai Y; Morishita Y; Miyazono K; Kato S; Saftig P; Takayanagi H
Science; 2008 Feb; 319(5863):624-7. PubMed ID: 18239127
[TBL] [Abstract][Full Text] [Related]
17. Cysteine cathepsins in the immune response.
Zavasnik-Bergant T; Turk B
Tissue Antigens; 2006 May; 67(5):349-55. PubMed ID: 16671941
[TBL] [Abstract][Full Text] [Related]
18. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
Robson NC; Donachie AM; Mowat AM
Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
